Loading...
XASX
BTC
Market cap13mUSD
Oct 08, Last price  
0.06AUD
1D
0.00%
Jan 2017
-51.30%
IPO
-86.73%
Name

BTC Health Ltd

Chart & performance

D1W1MN
XASX:BTC chart
P/E
576.41
P/S
680.43
EPS
0.00
Div yield, %
—
Shrs. gr., 5y
7.65%
Rev. gr., 5y
8.92%
Revenues
29k
+195.37%
13,0002,000303,00062,000-394,000-54,18747,31115,59611,35071,18428,49640,000170,000160,00019,19095,00413,26016,3609,96029,419
Net income
35k
-99.13%
-759,000-7,386,000-4,333,000-5,707,000-3,495,000-1,860,000-502,000-1,888,973-507,019-871,000-517,000-1,468,000-693,000-283,000-392,000-576,000-10,168,0001,055,0003,981,29834,728
CFO
-354k
L-29.22%
-547,000-493,000-508,000-740,000-519,000-342,187-422,931-145,675-209,529-162,700-388,366-555,524-655,800-492,023-366,152-392,911-433,608-404,757-499,981-353,880
Dividend
Oct 18, 20120.0154107 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BTC Health Limited operates as a Pooled Development Fund, overseen by LHC Capital Partners Pty Ltd. The fund strategically deploys capital across various corporate development stages, from initial seed and startup funding to early, mid, and late-stage venture growth, and into emerging and established growth companies. Its investment focus lies primarily within the healthcare and biotechnology industries, with a specific emphasis on groundbreaking areas such as post-genomics, which encompasses functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. It also targets stem cell biology, particularly stem cell therapies. Other key areas of interest include convergent technologies, like biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics; silicon biology, involving structure-based drug design, virtual screening, computational library design, and in silico ADME/tox; and nanomedicine. The fund exclusively supports businesses located in Australia, investing in both publicly traded and privately held enterprises.

Key people

Richard Treagus
Executive Chairman of the Board · since 2021
Josh Kahanovitz
Chief Operating Officer · since 2025
Tim Collins
Director of Sales, Director of Marketing
Chief Financial Officer, Company Secretary · since 2025
Martin Kahanovitz
Non-Executive Director · since 2025
Felicity Mcneill
Non-Executive Director · since 2022
IPO date
Aug 29, 2000
Employees
1
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT